





For more recipes, tips, and helpful resources, like us on Facebook.com/SandostatinLARDepot

This recipe was created by our RealSupport™ nutritionist especially for our members. Remember, please talk to your health care provider to determine if this recipe or any other food is appropriate for you.

SWEET POTATO POWER BOWL

(L')

Prep time: 10 minutes

(A)

Cook time: 25 minutes



Ready in: 35 minutes

Ingredients

For salad:

- 1 sweet potato, peeled and cut into ½-inch cubes
- 1 tablespoon extra-virgin olive oil
- 1 tablespoon cornstarch
- 1 teaspoon kosher salt
- ½ teaspoon black pepper
- 4 cups kale, stems removed and leaves roughly chopped
- 1 cup edamame, shelled and cooked
- 1 red bell pepper, diced
- 1 cup carrots, peeled and grated

For dressing:

- 2 tablespoons tahini
- 2 tablespoons lemon juice
- 1 tablespoon extra-virgin olive oil
- 1 tablespoon water
- 1 teaspoon freshly grated ginger
- ¼ teaspoon kosher salt
- ¼ teaspoon black pepper

Steps

- Preheat oven to 400°F. Line rimmed baking sheet with parchment paper. Toss sweet potatoes with extra-virgin olive oil, salt, and pepper and spread on prepared baking sheet. Bake for 20-25 minutes, flipping halfway through, until tender.
- 2. While sweet potatoes cook, whisk all ingredients for dressing in bowl until combined.
- 3. To make salad, combine kale, edamame, red peppers, and carrots in serving bowls. Top with sweet potato and drizzle with tahini dressing.

*Includes Sandostatin® (octreotide acetate) Immediate-Release Injection and Sandostatin® LAR Depot (octreotide acetate) for injectable suspension for all approved indications.

Please note that Novartis Pharmaceuticals Corporation does not endorse the use of any foods highlighted in this article; all information is provided for educational purposes only. Use of any food in this recipe is not intended to treat or cure carcinoid syndrome. You are advised to speak to your health care provider before introducing new foods into your diet.

Please see Indications and Important Safety Information on page 2.

Please click here for full Prescribing Information.

1

Brought to you by RealSupport[™], a patient information and support program for those with the severe diarrhea and flushing of carcinoid syndrome. RealSupport[™] is provided by Novartis Pharmaceuticals Corporation, the maker of Sandostatin[®] LAR Depot (octreotide acetate) for injectable suspension. For more information about RealSupport[™] program offerings, please follow us on www.facebook.com/SandostatinLARDepot.

INDICATIONS AND USAGE

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for full Prescribing Information.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com



